TKM-Ebola

TKM-Ebola was an experimental antiviral drug for Ebola disease that was developed by Arbutus Biopharma (formerly Tekmira Pharmaceuticals Corp.) in Vancouver, Canada.

Uses your system voice; voice and rate in settings.

≈ 3 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

TKM-Ebola was an experimental antiviral drug for Ebola disease that was developed by Arbutus Biopharma (formerly Tekmira Pharmaceuticals Corp.) in Vancouver, Canada. The drug candidate was formerly known as Ebola-SNALP.

TKM-Ebola is a combination of small interfering RNAs targeting three of the seven proteins in Ebola virus: Zaire Ebola L polymerase, Zaire Ebola membrane-associated protein (VP24), and Zaire Ebola polymerase complex protein (VP35). By down-regulating these three proteins, TKM-Ebola inhibits virus replication and eliminates the infection.

The drug was effective in rhesus monkeys infected with Ebola. After the Ebola outbreak in West Africa in 2014, the new variant responsible for it was isolated from several Ebola virus families and the specific genomic sequence was determined. The company re-designed TKM-Ebola and renamed it as "TKM-Ebola-Guinea".

In January 2014, Tekmira started a Phase I clinical trial of TKM-Ebola to assess its safety in healthy people with a dose of 0.24 mg/kg/day for seven day treatments. The FDA placed the trial on clinical hold in July 2014 to assess results, after some subjects had flu-like responses.

In August, the FDA changed the status to "partial hold", allowing the drug to be used under expanded access in people infected with Ebola but with the Phase I trial still suspended. In April 2015 the FDA allowed the study to resume at a lower dose.

A Phase II trial started on 11 March 2015 in Sierra Leone, West Africa and stopped enrolling new subjects on 19 June 2015 after it appeared not to work. In July 2015 the company announced it was changing its name to Arbutus, suspending development of the drug for Ebola and changing its focus to developing treatments for hepatitis B virus.

See also

Atoltivimab/maftivimab/odesivimab, treatment of Zaire ebolavirus (Ebola virus) Favipiravir ZMapp

Text derived from https://en.wikipedia.org/w/index.php?oldid=1186545887 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001186545887 · captured 2023-11-23 · ledger · version history

Cite this page as: encyclopegia.org, “TKM-Ebola”, snapshot enwiki-001186545887. https://encyclopegia.org/a/tkm-ebola

Sources cited in this revision

9 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.